Aurovertin B exerts potent antitumor activity against triple-negative breast cancer in vivo and in vitro via regulating ATP synthase activity and DUSP1 expression

被引:8
|
作者
Wu, Rui [1 ]
Yang, Xi [1 ]
Zhou, Qian [1 ]
Yu, Wenyan [1 ]
Li, Minwei [3 ]
Wo, Jianer [3 ]
Shan, Weiguang [1 ]
Zhao, Hong [4 ]
Chen, Yan [1 ,2 ]
Zhan, Zhajun [1 ]
机构
[1] Zhejiang Univ Technol, Coll Pharmaceut Sci, Hangzhou 310014, Peoples R China
[2] Zhejiang Univ Technol, Lab Anim Ctr, Hangzhou, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 1, Sch Med,State Key Lab Diag & Treatment Infect Dis, Collaborat Innovat Ctr Diag & Treatment Infect Di, Hangzhou, Peoples R China
[4] Zhejiang Chinese Med Univ, Affiliated Hosp, Hangzhou, Peoples R China
来源
PHARMAZIE | 2020年 / 75卷 / 06期
关键词
BIOENERGETIC SIGNATURE; MARKER; CELLS;
D O I
10.1691/ph.2020.0380
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Aurovertin B, a natural compound from Calcarisporium arbuscular, exhibits potent antiproliferative activity particularly against triple-negative breast cancer cells (TNBC), while having less cytotoxicity on normal breast cell MCF10A. However, very little is known about the in vivo antitumor activity of aurovertin B and the possible mechanism of the selective effect on triple-negative breast cancer cells. In this study, flow cytometry and DAPI staining analysis showed that aurovertin B treatment in human triple-negative breast cancer cell MDA-MB-231 could induce more apoptotic cells than taxol treatment group. Furthermore, the present study also revealed that aurovertin B induced apoptosis was due to regulation of ATP synthase activity rather than changes in gene expression. Interestingly, the cancer genome atlas (TCGA) data analysis implied that the expression level of DUSP1, a member of the dual-specificity phosphatases, was highly downregulated in breast tissue of TNBC patients compared with their adjacent normal tissues. Real-time PCR and western blot analyses further demonstrated that aurovertin B could dramatically increase mRNA and protein expression levels of DUSP1 in MDA-MB-231 cells but not in MCF10A cells. The potent anti-tumor activity of aurovertin B was further verified in a human MDA-MB-231 xenograft mouse model.
引用
收藏
页码:261 / 265
页数:5
相关论文
共 50 条
  • [21] New bis(hydroxymethyl) alkanoate curcuminoid derivatives exhibit activity against triple-negative breast cancer in vitro and in vivo
    Hsieh, Min-Tsang
    Chang, Ling-Chu
    Hung, Hsin-Yi
    Lin, Hui-Yi
    Shih, Mei-Hui
    Tsai, Chang-Hai
    Kuo, Sheng-Chu
    Lee, Kuo-Hsiung
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 131 : 141 - 151
  • [22] Discovery of novel metformin derivatives with potent antitumor activity in combination with immunotherapy for treatment of triple-negative breast cancer
    Marquez-Garban, Diana C.
    Deng, Gang
    Comin-Anduix, Begonya
    Muhunthan, Vishaka
    Ma, Gaoyuan
    Murphy, Jennifer
    Garcia, Alejandro J.
    Yanes, Cristian D.
    Burton, Lorena R.
    Hamilton, Nalo
    Shackelford, David
    Jung, Michael E.
    Pietras, Richard J.
    CANCER RESEARCH, 2020, 80 (16)
  • [23] Ferrocenyl Aminocresols Display Multimodal Activity Against Triple-Negative Breast Cancer Cells In Vitro
    Mhlanga, Richwell
    Mbaba, Mziyanda
    Tonui, Ronald
    Edkins, Adrienne L.
    Khanye, Setshaba D.
    de la Mare, Jo-Anne
    CHEMISTRYSELECT, 2024, 9 (42):
  • [24] A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells
    Fouque, Amelie
    Delalande, Olivier
    Jean, Mickael
    Castellano, Remy
    Josselin, Emmanuelle
    Malleter, Marine
    Shoji, Kenji F.
    Mac Dinh Hung
    Rampanarivo, Hariniaina
    Collette, Yves
    van de Weghe, Pierre
    Legembre, Patrick
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (16) : 6559 - 6573
  • [25] LPM3770277, a Potent Novel CDK4/6 Degrader, Exerts Antitumor Effect Against Triple-Negative Breast Cancer
    Qiu, Jiahao
    Bai, Xinfa
    Zhang, Wenjing
    Ma, Mingxu
    Wang, Wenyan
    Liang, Ye
    Wang, Hongbo
    Tian, Jingwei
    Yu, Pengfei
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [26] Discovery of novel steroidal-chalcone hybrids with potent and selective activity against triple-negative breast cancer
    Hou, Qiangqiang
    Lin, Xin
    Lu, Xiang
    Bai, Chengfeng
    Wei, Hanlin
    Luo, Guoshun
    Xiang, Hua
    BIOORGANIC & MEDICINAL CHEMISTRY, 2020, 28 (23)
  • [27] Axitinib alone or in combination with chemotherapeutic drugs exerts potent antitumor activity against human gastric cancer cells in vitro and in vivo
    Qiong He
    Jing Gao
    Sai Ge
    Tingting Wang
    Yanyan Li
    Zhi Peng
    Yilin Li
    Lin Shen
    Journal of Cancer Research and Clinical Oncology, 2014, 140 : 1575 - 1583
  • [28] Axitinib alone or in combination with chemotherapeutic drugs exerts potent antitumor activity against human gastric cancer cells in vitro and in vivo
    He, Qiong
    Gao, Jing
    Ge, Sai
    Wang, Tingting
    Li, Yanyan
    Peng, Zhi
    Li, Yilin
    Shen, Lin
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2014, 140 (09) : 1575 - 1583
  • [29] Pristimerin exerts antitumor activity against MDA-MB-231 triple-negative breast cancer cells by reversing of epithelial-mesenchymal transition via downregulation of integrin β3
    Liu, Shiyue
    Dong, Youhong
    Wang, Ying
    Hu, Pengchao
    Wang, Jing
    Wang, Robert Yl
    BIOMEDICAL JOURNAL, 2021, 44 (06) : S84 - S92
  • [30] Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines
    Terashima, Masato
    Sakai, Kazuko
    Togashi, Yosuke
    Hayashi, Hidetoshi
    De Velasco, Marco A.
    Tsurutani, Junji
    Nishio, Kazuto
    SPRINGERPLUS, 2014, 3